U.S. flag

An official website of the United States government

NIH: Fogarty International Center NIH: Fogarty International Center
Advancing Science for Global Health
Advancing Science for Global Health
Home > Global Health Matters Sep/Oct 2015 > Arsenic added to cancer therapy after studies in China Print

Arsenic added to cancer therapy after studies in China

September / October 2015 | Volume 14, Issue 5

Close-up of arsenic trioxide, a mound of white powder in the middle of a glass dish
Photo by Martin Walker via Wikimedia

Scientists in China discovered that the compound arsenic trioxide,
pictured above, worked as a treatment for people with acute
promyelocytic leukemia.

by Shana Potash

When some people hear the word "arsenic," they immediately think of poison. But the chemical also helps save the lives of people with a rare type of leukemia. Chinese scientists were first to identify arsenic as a treatment for acute promyelocytic leukemia (APL).

APL, which can cause life-threatening bleeding, used to be one of the most fatal forms of acute myeloid leukemia. Now, it's one of the most treatable types in adults, with about an 80 percent cure rate.

"The treatment of acute promyelocytic leukemia is a success story of modern hematology," noted Drs. Eytan Stein and Martin Tallman, of New York's Memorial Sloan Kettering, in an article published in the journal Oncology.

Arsenic has been known as a poison and medicine for more than 2,000 years. In the 1970s, scientists in China discovered that the compound arsenic trioxide worked for people with APL, including those whose leukemia returned after standard therapy. Clinical trials in the U.S. confirmed the findings and the FDA approved the treatment in 2000.

When it comes to APL, arsenic trioxide is "definitely not a poison; the data suggest that it is more of a magic potion," wrote Dr. Bayard Powell, in an article in Expert Review of Anticancer Therapy. Powell, of North Carolina's Wake Forest University, led some of the NIH-funded arsenic trioxide studies.

Before arsenic trioxide, there was another medical advance in the treatment of APL. In 1995, the FDA approved a drug that comes from vitamin A, all-trans retinoic acid (ATRA), based on clinical trials in the U.S., China and France.

Researchers say, together, ATRA and arsenic trioxide have transformed the APL treatment landscape.

More Information

To view Adobe PDF files, download current, free accessible plug-ins from Adobe's website.